Vidac Pharma Submits Clinical Study Application to EMA for Advanced Actinic Keratosis Lesions
Comprehensive dossier underscores rigorous scientific, clinical, and CMC preparation, with key support from CRO partners Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, September 15, 2025 / …